Innate Pharma: Advancing Oncology Therapies at ASH 2024

Innate Pharma, a pioneering biotechnology company focused on immunotherapies for cancer, recently announced the selection of multiple abstracts for presentation at the American Society of Hematology (ASH) Annual Meeting 2024. This significant milestone highlights the company's progress in developing innovative treatments for various hematological malignancies.

The selected abstracts represent a diverse range of Innate Pharma's programs, showcasing the breadth of its research and development efforts. One notable presentation, "Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the TELLOMAK Phase 2 Trial" (Abstract Number: 1609), focuses on the company's lead proprietary asset, lacutamab. This first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody is currently being investigated in clinical trials for the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL).

Another compelling abstract, "Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated by Lacutamab: Patient-Reported Outcomes from the Phase 2 TELLOMAK Trial" (Abstract: 466), will present patient-reported outcomes from the Phase 2 TELLOMAK trial. This data will provide valuable insights into the impact of lacutamab on patients' quality of life, a crucial factor in assessing the overall effectiveness and acceptability of a therapy.

Innate Pharma's collaboration with Sanofi is also well-represented at the ASH Annual Meeting. The abstract "Phase 1/2, Open-Label, Multi-Center Study Assessing the Safety, Tolerability and Preliminary Efficacy of CD123 Natural Killer Cell Engager (NKCE), SAR443579, in Combination With Venetoclax and Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy (Sanofi)" (Abstract: 2883.3) highlights the potential of the multi-specific NK cell engagers from the ANKET® platform in combination with other therapies.


The ASH Annual Meeting serves as an ideal platform for Innate Pharma to showcase its advancements and connect with key opinion leaders in the field of hematology. The selected abstracts not only demonstrate the company's commitment to innovation but also underscore its potential to make a significant impact on the lives of patients with hematological malignancies.

As Innate Pharma continues to advance its oncology therapies, investors should keep a close eye on the company's progress. The positive data and recognition at the ASH Annual Meeting may bode well for the company's future and its potential to create value for shareholders.